Randomized, double-blind trial to show the efficacy of daiobotanpito as additional option in treating acute diverticulitis - RCT to show the efficacy of daiobotanpito as additional option in treating acute diverticulitis

Department of Japanese-Traditional (Kampo) Medicine, Kanazawa University Hospital0 个研究点目标入组 170 人开始时间: 2017年5月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with severe dysfunction in the following organs, based on blood tests within four weeks before treatment starts Renal function serum creatinine value 1.5-fold greater than the upper limit of the institutional standard Liver function serum AST value or serum ALT value 3-fold greater than the upper limit of the institutional standard Central nervous function encephalopathy or a patient suspected of it Electrolytes serum sodium less than 125, serum potassium less than 3.3 2. Patients considered highly likely to exhibit abscess perforation due to malnutrition, serum Albumin less than 2.5 3. Patients with symptoms of obstructive ileus 4. Patients who exhibit chronic anorexia, abdominal pain, and/or diarrhea symptoms before the onset of colorectal diverticulitis 5. Before the onset of colorectal diverticulitis, performance status, an indicator of general condition and the degree of restriction of the patient's daily life, of more than three 6. Patients who have a history of DBT administration 7. Patients undergoing treatment with insulin preparations 8. Immunocompromised patients 9. Pregnant women and those in the postpartum period 10. Patients with advanced allergy to Kampo formulas 11. Patients who the doctor considers to be inappropriate for inclusion in this study.

发起方

Department of Japanese-Traditional (Kampo) Medicine, Kanazawa University Hospital